{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:49:42Z","timestamp":1794851382380,"version":"4.9.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Inflammatory bowel disease (IBD), encompassing Crohn\u2019s disease and ulcerative colitis, impose an escalating burden on healthcare systems globally, with a rising prevalence contributing to increased costs. This study explored healthcare utilisation patterns and its drivers amongst IBD patients in an outpatient clinic.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A longitudinal cohort study was conducted at a Dutch academic teaching hospital. IBD patients (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2005=\u2005180) were followed for 1\u2005year and were categorised based on disease activity and consultation frequency. Healthcare utilisation was assessed through consultations and laboratory tests. Patient-reported outcomes and biochemical disease activity were measured, and subsequently the reasons for consultations were analysed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The frequency of outpatient healthcare utilisation exceeded the recommended IBD care guidelines by two-fold. Comorbidities were the leading reason for consultations (40.4%), followed by remission induction, medication changes and pending test results. Moreover, clinical disease activity, reported problems with self-care, daily activities and pain were predictive of an increase in annual consultations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study identified factors influencing healthcare utilisation in IBD outpatients. Personalised care pathways using eHealth technologies have the potential to reduce unnecessary consultations and optimise resource allocation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/meg.0000000000002880","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T17:00:45Z","timestamp":1731085245000},"page":"176-183","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Healthcare utilisation patterns and drivers amongst inflammatory bowel disease patients in the outpatient clinic"],"prefix":"10.1097","volume":"37","author":[{"given":"Lola J.M.","family":"Koppelman","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.W. Jeroen","family":"Maljaars","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip W.","family":"Voorneveld","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E.","family":"van der Meulen-de Jong","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"R2-20250430","doi-asserted-by":"crossref","first-page":"e0160264","DOI":"10.1371\/journal.pone.0160264","article-title":"Time trends in prevalence of chronic diseases and multimorbidity not only due to aging: data from general practices and health surveys.","volume":"11","author":"van Oostrom","year":"2016","journal-title":"PLoS One"},{"key":"R4-20250430","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/jgh.14872","article-title":"The epidemiology of inflammatory bowel disease: east meets west.","volume":"35","author":"Mak","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"R5-20250430","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"R6-20250430","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study.","volume":"63","author":"Mirthe Emilie van der","year":"2014","journal-title":"Gut"},{"key":"R7-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ibd\/izz104","article-title":"The cost of inflammatory bowel disease: an initiative from the Crohn\u2019s & colitis foundation.","volume":"26","author":"Park","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"R8-20250430","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s10620-020-06329-9","article-title":"A phenome-wide analysis of healthcare costs associated with inflammatory bowel diseases.","volume":"66","author":"Cai","year":"2021","journal-title":"Dig Dis Sci"},{"key":"R9-20250430","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","article-title":"The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission.","volume":"8","author":"Burisch","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R11-20250430","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(17)31327-2","article-title":"Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial.","volume":"390","author":"de Jong","year":"2017","journal-title":"Lancet"},{"key":"R12-20250430","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.cgh.2021.08.048","article-title":"Interventions to decrease unplanned healthcare utilization and improve quality of care in adults with inflammatory bowel disease: a systematic review.","volume":"20","author":"Fudman","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R14-20250430","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ajg.2015.120","article-title":"C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis.","volume":"110","author":"Mosli","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R15-20250430","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.cgh.2015.10.035","article-title":"Development and validation of an inflammatory bowel diseases monitoring index for use with mobile health technologies.","volume":"14","author":"Van Deen","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R16-20250430","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument.","volume":"4","author":"Reilly","year":"1993","journal-title":"PharmacoEcon"},{"key":"R17-20250430","first-page":"1571","article-title":"The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn\u2019s Relapse Prevention Trial.","volume":"91","author":"Irvine","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"R18-20250430","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0895-4356(98)00163-2","article-title":"The effect of adding a cognitive dimension to the EuroQol multiattribute health-status classification system.","volume":"52","author":"Krabbe","year":"1999","journal-title":"J Clin Epidemiol"},{"key":"R19-20250430","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","article-title":"Dutch tariff for the five-level version of EQ-5D.","volume":"19","author":"Versteegh","year":"2016","journal-title":"Value Health"},{"key":"R20-20250430","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment.","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R21-20250430","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment.","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R22-20250430","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications.","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis"},{"key":"R23-20250430","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/MEG.0b013e32836019b9","article-title":"Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease: results from the Swiss Inflammatory Bowel Disease Cohort Study.","volume":"25","author":"Sulz","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R24-20250430","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/00042737-199809000-00010","article-title":"Predictors of health care utilization in patients with inflammatory bowel disease: a longitudinal study.","volume":"10","author":"de Boer","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R25-20250430","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1097\/MIB.0000000000000763","article-title":"Demographic and clinical predictors of high healthcare use in patients with inflammatory bowel disease.","volume":"22","author":"Click","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"R26-20250430","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/ecco-jcc\/jjad075","article-title":"Management of inflammatory bowel disease using e-health technologies: a systematic review and meta-analysis.","volume":"17","author":"Kuriakose Kuzhiyanjal","year":"2023","journal-title":"J Crohns Colitis"},{"key":"R27-20250430","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/ecco-jcc\/jjaa126","article-title":"Inflammatory bowel disease in the COVID-19 pandemic: the patients\u2019 perspective.","volume":"14","author":"Grunert","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R29-20250430","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/ecco-jcc\/jjy020","article-title":"Second N-ECCO consensus statements on the European nursing roles in caring for patients with Crohn\u2019s disease or ulcerative colitis.","volume":"12","author":"Kemp","year":"2018","journal-title":"J Crohns Colitis"},{"key":"R30-20250430","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.dld.2017.08.026","article-title":"E-health in inflammatory bowel diseases: more challenges than opportunities?","volume":"49","author":"Bossuyt","year":"2017","journal-title":"Dig Liver Dis"},{"key":"R31-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41687-021-00366-2","article-title":"Patient perspectives on digital patient reported outcomes in routine care of inflammatory bowel disease.","volume":"5","author":"Nielsen","year":"2021","journal-title":"J Patient Rep Outcomes"},{"key":"R32-20250430","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ecco-jcc\/jjac187","article-title":"ECCO guidelines on inflammatory bowel disease and malignancies.","volume":"17","author":"Gordon","year":"2023","journal-title":"J Crohns Colitis"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T06:39:06Z","timestamp":1746081546000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000002880","relation":{},"ISSN":["0954-691X","1473-5687"],"issn-type":[{"value":"0954-691X","type":"print"},{"value":"1473-5687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]}}}